AstraZeneca, Durvalumab
AstraZeneca Pharma receives nod for cancer drug Durvalumab; stock soars 12%
The uptick in AstraZeneca share price came after the company announced that it has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL sol from CDSO.
AstraZeneca Pharma shares rally 13%, hit 52-week high after receiving nod for cancer drug Durvalumab
The stock is trading above its 5-day, 10-day, 20-day, 30-day, 50-day, 100-day, 150-day, and 200-day simple moving averages (SMAs).
AstraZeneca shares rally 13%, hit record high as firm gets nod for cancer drug
Astrazeneca Pharma India has received CDSO's (Central Drugs Standard Control Organisation) nod for the import of Durvalumab for its sale and distribution.
AstraZeneca Pharma gets nod to sell immunotherapy drug Durvalumab; stock surges
This surge came after the company announced approval to import and distribute Durvalumab (Imfinzi) infusion in two dosages.
AstraZeneca Pharma Gets Approval To Import And Distribute Durvalumab For Cancer Treatment
This approval allows Durvalumab to be used together with chemotherapy before surgery, and then as a single treatment afterward.
Lung cancer drug: AstraZeneca India wins CDSCO nod for Durvalumab for specified additional indication
Bengaluru: AstraZeneca Pharma India Limited has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution for infusion from the Central
AstraZeneca Pharma Surges on CDSO Approval for Durvalumab in India
AstraZeneca Pharma India has received approval from the CDSO for the import, sale, and distribution of Durvalumab.
AstraZeneca Stock Falls After Disappointing Results in Breast Cancer Drug Trial
Key Takeaways A breast cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer than with chemotherapy in a phase 3 trial.The trial included over 700 patients with inoperable or metastatic breast cancer.
AstraZeneca Pharma gets nod to launch cancer drug durvalumab in India
The approved indication involves using durvalumab in combination with chemotherapy as a neoadjuvant treatment, followed by durvalumab monotherapy post-surgery. Shares of Astrazeneca Pharma India Ltd ended at ₹6,
Cure Today9h
Imfinzi Improves Survival Outcomes in Subgroups of Patients with LS-SCLC
Among patients with limited-stage small cell lung cancer, the benefits of consolidation Imfinzi were seen across a number of ...
Medscape7d
'One of the Most Impactful' ESMO Studies: Durvalumab in Muscle-Invasive Bladder Cancer
BARCELONA — Adding the immune checkpoint inhibitor durvalumab to standard treatment for muscle-invasive bladder cancer (MIBC) ...
oncnursingnews11d
Postsurgical Durvalumab Does Not Boost DFS in Lung Cancer
Adjuvant durvalumab failed to improve disease-free survival in resected EGFR- or ALK-negative non-small cell lung cancer.
Adjuvant durvalumab extends survival in small cell lung cancer
For patients with limited-stage small cell lung cancer, adjuvant therapy with durvalumab leads to significantly longer ...
Medscape10d
No DFS Benefit With Adjuvant Durvalumab in Early NSCLC
The lack of a disease-free survival benefit with adjuvant durvalumab in early-stage resected non-small cell lung cancer in ...